Abstracts tagged "Lupus nephritis and treatment"

Abstract Number: 2666 • 2018 ACR/ARHP Annual Meeting
Trends in Treatment of Systemic Lupus Erythematosus and Lupus Nephritis: 2006-2016
Ali Duarte-Garcia¹, Cynthia S. Crowson², Rozalina McCoy¹, Stephanie Schilz³, Holly Van Houten⁴, Lindsey Sangaralingham⁴, Vaidehi R. Chowdhary⁵, Shreyasee Amin⁶, Kenneth J. Warrington⁷, Eric L. Matteson⁸ and Nilay Shah⁹, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, ⁵Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁶Rheumatology, Mayo Clinic, Rochester, MN, ⁷Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, ⁸Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁹Health Care Policy and Research, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Glucocorticoids, anti-malarials and conventional immunosuppressive agents have been the mainstay of therapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN); more recently biologic…
Abstract Number: 670 • 2017 ACR/ARHP Annual Meeting
Membrane Attack Complex (MAC) Deposition in Lupus Nephritis Is Associated with Hypertension and Poor Clinical Response to Treatment
Shudan Wang¹, Ming Wu², Luis Chiriboga³, Briana Zeck⁴ and H. Michael Belmont⁵, ¹Department of Medicine, Division of Rheumatology, New York University School Medicine, New York City, NY, ²New York University School of Medicine, New York, NY, ³Pathology, New York University School Medicine, New York, NY, ⁴Pathology, New York University School Medicine, New York City, NY, ⁵Medicine, New York University School of Medicine, New York, NY
Background/Purpose: LN is characterized by deposition of immune complexes in the kidney. Activation of the classical complement pathway by dsDNA is believed to play a…
Abstract Number: 885 • 2017 ACR/ARHP Annual Meeting
48-Week Complete Remission By Ethnic, Sex and Age Subgroups in Patients with Active Lupus Nephritis Treated with Voclosporin
David Wofsy¹, David A. Isenberg², Frédéric A. Houssiau³, Mary Anne Dooley⁴, Neil Solomons⁵ and Simrat Randhawa⁶, ¹Rheumatology, UCSF, San Francisco, CA, ²Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ³Rheumatology, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ⁴UNC Kidney Centre, Chapel Hill, NC, ⁵Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, ⁶Medical Affairs, Aurinia Pharmaceuticals, Victoria, BC, Canada
Background/Purpose: Voclosporin (VCS) is a novel CNI with a favorable metabolic profile, no observed effect on electrolytes, and a predictable dose response potentially eliminating the…
Abstract Number: 988 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Renal Remission, Relapse and Long-Term Renal Function Decline in Lupus Nephritis Treated with Combined Prednisolone and Mycophenolate Mofetil (MMF) or Tacrolimus (Tac)
Chi Chiu Mok¹, Ling Yin Ho², Chi Hung To³ and Kar Li Chan¹, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong, ³Medicine, Pok Oi Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the factors associated with renal remission, relapse and renal function decline in patients with lupus nephritis treated with combined steroid and MMF or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].